Dianthus Therapeutics, Inc. reported $2.0M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.0M (to Q4 2025). Net income: −$192M, trailing twelve months to Q2 2026. Free cash flow: −$156M, trailing twelve months to Q2 2026. Operating margin: −13902%, trailing twelve months to Q4 2025.

DNTHDianthus Therapeutics, Inc.

Healthcare

$82.35+124% 1Y

$82.35

$32.9252 weeks$115.67

DNTH as reported

Dianthus Therapeutics, Inc. reported $2.0M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

$2.0M

Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied

Net income: −$192M
Net income · +68% year on year · trailing twelve months to Q2 2026
Free cash flow: −$156M
Free cash flow · +55% year on year · trailing twelve months to Q2 2026
Operating margin: −13902%
Operating margin · trailing twelve months to Q4 2025

Details›

Every series Ryufin has for DNTH, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.0M	n/a	Q4 2025
Net income	−$192M	+68%	Q2 2026
EPS	−$4.24	+30%	Q2 2026
Operating margin	−13902%	n/a	Q4 2025
Net margin	−12724%	n/a	Q4 2025
ROE	−22%	n/a	Q2 2026
ROA	−21%	n/a	Q2 2026
Free cash flow	−$156M	+55%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.